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Alternative splicing (AS) defects that adversely affect
gene expression and function have been identified in
diabetic hearts; however, the mechanisms respon-
sible are largely unknown. Here, we show that the
RNA-binding protein RBFOX2 contributes to tran-
scriptome changes under diabetic conditions.
RBFOX2 controls AS of genes with important roles
in heart function relevant to diabetic cardiomyopa-
thy. RBFOX2 protein levels are elevated in diabetic
hearts despite low RBFOX2 AS activity. A domi-
nant-negative (DN) isoform of RBFOX2 that blocks
RBFOX2-mediated AS is generated in diabetic
hearts. DN RBFOX2 interacts with wild-type (WT)
RBFOX2, and ectopic expression of DN RBFOX2 in-
hibits AS of RBFOX2 targets. Notably, DN RBFOX2
expression is specific to diabetes and occurs at early
stages before cardiomyopathy symptoms appear.
Importantly, DN RBFOX2 expression impairs intra-
cellular calcium release in cardiomyocytes. Our re-
sults demonstrate that RBFOX2 dysregulation by
DN RBFOX2 is an early pathogenic event in diabetic
hearts.
INTRODUCTION
Diabetic patients have a 2- to 5-fold increased risk of developing
cardiovascular diseases, which include atherosclerosis, hyper-
tensive heart disease, and diabetic cardiomyopathy (Trachanas2200 Cell Reports 15, 2200–2213, June 7, 2016 ª 2016 The Author(s
This is an open access article under the CC BY-NC-ND license (http://et al., 2014). Cardiovascular complications are the number one
cause of mortality and morbidity among diabetic patients (Fer-
rannini and Cushman, 2012; Harcourt et al., 2013). Diabetic
cardiomyopathy is particularly difficult to manage due to its
asymptomatic nature and its ability to progress into heart failure
(Aneja et al., 2008; Asghar et al., 2009; Boudina and Abel, 2010).
The molecular mechanisms responsible for diabetic cardiomy-
opathy are poorly understood, though chronic activation of
protein kinase C (PKC) signaling has been implicated in the path-
ogenesis (Geraldes and King, 2010; Inoguchi et al., 1992; Liu
et al., 2009). Inhibition of PKC activity improves cardiac compli-
cations in animal models of diabetes (Connelly et al., 2009; Liu
et al., 2012) by mechanisms that are not well defined.
We have previously shown that PKC activation leads to reac-
tivation of fetal alternative splicing (AS) programs in diabetic
hearts partly via phosphorylation of the RNA-binding protein
RBFOX2 (Verma et al., 2013). Consistent with this finding, we
have shown that RBFOX2 protein levels are elevated in diabetic
mouse hearts (Verma et al., 2013), suggesting a role for RBFOX2
in the pathogenesis of diabetes. In this study, we wanted to
further investigate how RBFOX2 regulation is modulated in dia-
betic hearts andwhether changes in RBFOX2 contribute to aber-
rant AS in diabetes.
RBFOX2 directly binds to the consensus (U)GCAUG motif in
target pre-mRNAs and regulates AS in a position-dependent
manner. Binding to the downstream intron induces alternative
exon inclusion, but binding to the upstream intron triggers
exon exclusion (Huang et al., 2012; Sun et al., 2012; Yeo et al.,
2009). Genome-wide RBFOX2 target pre-mRNAs have been
identified using cross-linking IP followed by RNA sequencing
(CLIP-seq) analysis in human and mouse embryonic stem cells
(ESCs) and human 293T cells (Jangi et al., 2014; Lovci et al.,).
creativecommons.org/licenses/by-nc-nd/4.0/).
2013; Yeo et al., 2009). RBFOX2 controls the expression of other
RNA-binding proteins via AS-induced nonsense-mediated
mRNA decay (Jangi et al., 2014; Yeo et al., 2009). Therefore,
RBFOX2 affects gene expression at multiple levels, either
directly or indirectly via modulating other RNA-binding proteins.
RBFOX2 is implicated in several cellular processes such as
apoptosis, proliferation, and epithelial-mesenchymal transition
(Baraniak et al., 2006; Gehman et al., 2012; Venables et al.,
2013a). RBFOX2 is necessary for the survival of ESCs (Yeo
et al., 2009) and brain development (Gehman et al., 2012). It
also plays an important role in differentiation of pluripotent
stem cells (Venables et al., 2013b). A recent study has shown
that RBFOX2 is implicated in pressure-overload-induced heart
failure (Wei et al., 2015). However, its role in diabetes is unknown.
In this study, we show that 704 alternative exons differentially
spliced in diabetic hearts are RBFOX2 targets. We find that
RBFOX2 regulates AS of transcripts with validated RBFOX2-
binding sites. Results indicate that AS changes in RBFOX2 tar-
gets are due to low RBFOX2 levels or activity in diabetic hearts.
However, RBFOX2 protein levels are paradoxically elevated in
type 2 diabetic (T2D) human patients’ hearts. Our results reveal
that the mechanism for low RBFOX2-dependent AS in diabetes
is due to the increased expression of a dominant-negative (DN)
isoform of RBFOX2, which possesses an inhibitory AS function.
DN RBFOX2 is expressed early in response to high glucose
levels in diabetic mice and is specific to diabetic complications
in the heart. We show that DN RBFOX2 generation in diabetic
hearts is dependent on upregulation of RBFOX2 protein with
intact RNA-binding capability. Overexpression of DN RBFOX2
inhibits AS of RBFOX2 targets and impairs intracellular calcium
handling in cardiomyocytes. Finally, our data indicate that DN
RBFOX2 binds to wild-type (WT) RBFOX2 as a likely mechanism
to repress RBFOX2 splicing function. In sum, our results demon-
strate that dysregulation of RBFOX2 activity triggers AS abnor-
malities and contributes to diabetic complications in the heart.
RESULTS
RBFOX2-Binding Sites Are Enriched in Pre-mRNAs that
Undergo AS Changes in Diabetic Hearts
We have previously identified genome-wide AS changes in
type 1 diabetic (T1D) mouse hearts with a corresponding in-
crease in RBFOX2 protein levels (Verma et al., 2013). Therefore,
we hypothesized that RBFOX2 is involved in AS dysregulation in
diabetic hearts. Because genome-wide RBFOX2-binding sites
were determined using human ESCs by CLIP-seq (Yeo et al.,
2009), we wanted to determine whether transcripts mis-spliced
in diabetic mouse hearts have RBFOX2-binding sites. To this
end, we mapped the human RBFOX2-binding sites to the corre-
spondingmouse genomic coordinates. Seventy-three percent of
total pre-mRNAs mis-spliced in diabetic hearts displayed
RBFOX2-binding clusters within alternative exons and introns
(adjacent 500 nt; Figure 1A). For controls, transcripts with similar
expression levels but that did not display splicing changes in dia-
betic hearts were used. The majority (1,023 out of 1,417) of
RBFOX2-binding clusters were located within introns (Figure 1B)
consistent with the role of RBFOX2 in AS regulation. RBFOX2-
binding clusters within intronic regions of mis-spliced transcriptswere statistically significant when compared to binding clusters
within control transcripts (Figures 1B and S1). To determine the
functions of the affected RBFOX2 target genes in diabetic
hearts, we performed gene ontology analysis using the NIAID
Database for Annotation, Visualization and Integrated Discovery
(DAVID) server using the whole genome as a background con-
trol. RBFOX2 target genes dysregulated in diabetic hearts have
important biological functions in macromolecular metabolism,
apoptosis, vesicular transport, calcium homeostasis, and cell
cycle (Figure 1C).
RBFOX2 Regulates AS Events Mis-spliced in Diabetic
Hearts
Next, we wanted to determine whether RBFOX2 regulates AS of
the pre-mRNAs with RBFOX2-binding sites. We validated 22 out
of 24 tested AS events identified by RNA-seq in T1D diabetic
mouse hearts and 8 out of 11 tested AS events in T2D human
hearts (data not shown). We further focused on a few AS events
based on the criteria that (1) there is a significant AS change
(>20%) in diabetic hearts, (2) AS removes a functional protein
domain (Figure 1D), (3) the genes play important roles in heart
function and disease (Figure 1D): MTMR3 (Lorenzo et al., 2006;
Taguchi-Atarashi et al., 2010); FXR1 (Blackwell et al., 2010; Kirk-
patrick et al., 1999; Mientjes et al., 2004; Whitman et al., 2011);
MEF2A (Mora and Pessin, 2000; Naya et al., 2002; Wang et al.,
2003; Weng et al., 2005; Zhu et al., 2005); and PBX3 (Arrington
et al., 2012; Monica et al., 1991; Stankunas et al., 2008), and
(4) pre-mRNAs display distinct RBFOX2-binding sites in up-
stream or downstream intronic regions (Figure 1E). By examining
the AS of these specific exons with intronic RBFOX2-binding
sites (Figure 1E), we would be able to assess whether increased
RBFOX2 levels correspond to diabetes-induced AS changes in
the heart.
We tested AS of these four pre-mRNAs (MTMR3 exon 16,
FXR1 exon 15+16,MEF2A exon 9, and PBX3 exon 7) in T2D hu-
man hearts as well as in obese and hypertensive mouse models
using qRT-PCR. Obesity and hypertension are common among
diabetic patients, so we wanted to determine whether AS
changes are induced by one of these factors under diabetic con-
ditions.MTMR3 exon 16, FXR1 exon 15+16,MEF2A exon 9, and
PBX3 exon 7 were skipped more in T2D human patients’ hearts
compared to non-diabetic control human hearts, similar to the
results in T1D mice (Figure 2A; Verma et al., 2013). However,
none of these AS events changed in obese, hypertensive, or
obese-hypertensive mice (Figures 2B and S2). Mice infused
with angiotensin II had hypertrophic hearts, and obese mice
were two times heavier than the controls (Figures 2C and 2D;
Tieu et al., 2009). These data suggest that diabetes-induced
AS changes are independent of hypertension or obesity status.
We tested these AS events in mice with advanced cardiomyop-
athy and heart failure in order to determine whether AS changes
are due to non-specific effects from failing hearts. None of the AS
events was altered in chagasic mice with chronic cardiomyopa-
thy and heart failure (Figure 2E; Gupta et al., 2015), indicating
that AS changes were not due to sick hearts. Importantly, the
alternative exons with downstream RBFOX2-binding sites were
excluded in diabetic patients, suggesting low RBFOX2 levels
or AS activity under diabetic conditions.Cell Reports 15, 2200–2213, June 7, 2016 2201
Figure 1. Seventy-Three Percent of Transcripts Aberrantly Spliced in Diabetic Mouse Hearts Have RBFOX2-binding Sites
(A) Pie chart of RBFOX2-binding clusters in 967 transcripts that are mis-spliced in type 1 diabetic (T1D) mouse hearts. Alternative splicing (AS) events affected in
diabetic hearts with at least one CLIP peak at a Bayes factorR 1 were designated as ‘‘significant’’ and <1 as ‘‘not significant.’’
(B) RBFOX2-binding site distribution among 1,417 RBFOX2-binding clusters within 704 pre-mRNAs aberrantly spliced in diabetic hearts (see Figure S1).
(C) Top gene ontology categories for RBFOX2-regulated genes affected in diabetic hearts. DAVID server was used to categorize genes based on biological or
molecular function. p values represent statistical significance when compared to the whole genome, which was used as a background control.
(D) Effect of diabetes-induced AS changes on gene expression and function.
(E) Schematic of intronic RBFOX2-binding sites obtained from human ESCRBFOX2 CLIP-seq data with CLIP clusters and consensus RBFOX2-binding site motif
(U)GCAUG on target pre-mRNAs mis-spliced in diabetic hearts.
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Figure 2. AS of RBFOX2 Targets Is Disrupted in Diabetic Hearts Independent of Hypertension and Obesity
(A) Percent inclusion of MTMR3 exon 16, FXR1 exon 15+16, MEF2A exon 9, and PBX3 exon 7 as determined by qRT-PCR in non-diabetic (control) or type 2
diabetic (T2D) human left ventricles (nR 3).
(B) AS analysis of Mtmr3 exon 16 in hypertensive, obese, and obese-hypertensive mouse models (see also Figure S2; n = 3).
(C) Body weight of mock-treated control, angiotensin-II-treated hypertensive, obese, and angiotensin-II-treated obese mice.
(D) Heart-to-body-weight ratio of mock-treated control mice or angiotensin-II-treated hypertensive mice.
(E) AS analysis in chagasic mice with severe cardiomyopathy and heart failure. Mtmr3 exon 16, Fxr1 exon 15+16, Mef2a exon 9, and Pbx3 exon 7 AS was
determined in non-infected (control) or chronically infected chagasic mice with cardiomyopathy (cardiomyopathy; nR 3).
Data represent means ± SD. Statistical significance was calculated using unpaired t test for two group comparisons or using one-way ANOVA to compare four
different groups. p values are represented as **** < 0.0001, *** < 0.001, ** < 0.01, and * < 0.05.To further investigate whether decreased RBFOX2 levels
induce the AS patterns of diabetic hearts, we performed
RBFOX2 depletion studies in rat-heart-derived cells (H9c2) andtested endogenous AS events dysregulated in diabetic hearts.
We used both small interfering RNA (siRNA) and small hairpin
RNA (shRNA) to target different regions of Rbfox2 (Figure 3A).Cell Reports 15, 2200–2213, June 7, 2016 2203
Figure 3. RBFOX2 Regulates AS Events Altered in Diabetic Hearts
(A) Schematic of Rbfox2 pre-mRNA (only exons 3–7) regions targeted by siRNA and shRNA. Introns were not drawn to scale.
(B) Total protein lysates from siRNA-treated H9c2 cells analyzed by western blotting (WB) using an antibody (Ab) against RBFOX2 to determine the depletion
efficiency of Rbfox2 siRNA. GAPDH WB was performed to confirm even protein loading.
(C) RBFOX2 protein levels determined in shRNA-expressing H9c2 cells by WB using an anti-RBFOX2 Ab. GAPDH WB was used as a loading control.
(D) AS analysis ofMtmr3 exon 16, Fxr1 exon 15+16,Mef2a exon 9, and Pbx3 exon 7 in H9c2 cells transfected with scrambled (control) or Rbfox2-specific siRNA
(targets exon 6; nR 8).
(E) AS analysis in H9c2 cells transfected with scrambled (control) or Rbfox2-specific shRNA (targets exon 3; nR 6).
In AS gel figures, +E# is exon no. inclusion andE# is exon no. exclusion. Data represent the means ± SD. The unpaired t test was used to calculate statistically
significant differences between two sample groups from three independent experiments. p values are indicated as **** < 0.0001 and *** < 0.001.
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Figure 4. DN RBFOX2 Is Generated in Diabetic Hearts at Early Stages
(A) WB analysis of RBFOX2 protein in non-diabetic control or T2D human left ventricles using an anti-RBFOX2 Ab. a-TUBULINWBwas used as a loading control.
Fold change in RBFOX2 protein levels was determined after normalizing protein levels to a-TUBULIN, the control averages were set to 1, and patient averages
were summarized below.
(B) Relative RBFOX2 mRNA levels in non-diabetic control and T2D human patients’ hearts, determined by qRT-PCR (nR 5).
(C) Schematic of DN RBFOX2 generation via exon 6 exclusion (RRM, RNA recognition motif). Introns were not drawn to scale.
(legend continued on next page)
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Alternative exons with RBFOX2-binding sites (Mtmr3 exon 16,
Fxr1 exon 15+16, andMef2a exon 9; Figure 1E) had less exon in-
clusion in RBFOX2-depleted cells (Figures 3B and 3D), similar to
that in diabetic hearts (Figure 3D versus Figure 2A). As an addi-
tional control, we depleted RBFOX2 using an shRNA targeting a
different region in the Rbfox2mRNA (exon 3; Figures 3A and 3C)
to make sure that changes in AS were due to specific depletion
of RBFOX2. Cells expressing Rbfox2-specific shRNA displayed
AS patterns similar to those in Rbfox2 siRNA-treated cells (Fig-
ure 3E versus Figure 3D) and in T2D human patients’ hearts (Fig-
ure 2A), indicating that low RBFOX2 levels or activity trigger the
AS patterns of diabetes. AS of Pbx3 was unaffected in Rbfox2
siRNA-treated cells (Figure 3D), consistent with its lack of
RBFOX2-binding sites (Figure 1E), but was affected in Rbfox2
shRNA-treated cells (Figure 3E). It is possible that PBX3 could
be an indirect downstream target of RBFOX2 because its
AS was altered only after prolonged shRNA treatment. These re-
sults show that pre-mRNAs with RBFOX2-binding sites are
differentially spliced in T2D human hearts, consistent with low
RBFOX2-dependent splicing.
High RBFOX2 Protein Levels in Diabetic Hearts Are
Consistent with Increased Expression of a DN Isoform of
RBFOX2
We have previously shown that RBFOX2 protein levels are
elevated in T1D mouse hearts (Verma et al., 2013), which is con-
tradictory to our new findings of low RBFOX2 AS activity in
diabetic hearts. We thought that RBFOX2 might be regulated
differently in T2D versus T1D. Therefore, we tested RBFOX2 pro-
tein levels in T2D human patients’ hearts. Consistent with our
data in T1D mice, RBFOX2 protein levels were also elevated in
T2D patients’ hearts (Verma et al., 2013; Figure 4A). To deter-
mine whether the increase in RBFOX2 protein levels was due
to increased mRNA levels, we performed qRT-PCR using
RBFOX2-specific primers in T2D patients’ hearts and age-
matched non-diabetic controls. There was no significant in-
crease in RBFOX2 mRNA levels in diabetic hearts (Figure 4B)
that could explain high protein levels (Figure 4A), suggesting
that RBFOX2 protein levels are regulated post-transcriptionally.
To better understand how RBFOX2 is dysregulated in diabetic
hearts, we examined the expression of a DN RBFOX2 isoform
that is capable of repressing the AS activity of RBFOX family of
proteins (including RBFOX1, RBFOX2, and RBFOX3; Damianov
and Black, 2010; Nakahata and Kawamoto, 2005). DN RBFOX2
is generated via exclusion of exon 6, which encodes half of
the RNA recognition motif (RRM), resulting in low RNA-binding
capability and newly gained RBFOX repressor activity (Damia-(D) DN RBFOX2 mRNA levels were determined by RBFOX2 exon 6 exclusion
controls (nR 5).
(E) DN Rbfox2 expression in hearts from non-diabetic control mice or non-obese
(F) DN Rbfox2 expression in hearts from mock-injected control or streptozotocin
(G–I) Cardiac function of mice before (pre-STZ) or 3 weeks after hyperglycemia
fractional shortening (%), (H) stroke volume (vol.), and (I) ventricular internal diam
(J) DN Rbfox2 expression in left ventricles from chagasic mice with severe cardio
(K) DN Rbfox2 expression pattern in left ventricles of obese, hypertensive, and o
Data represent the means ± SD. Statistical significance between two groups was
ANOVA. p values are indicated as *** < 0.001 and ** < 0.01.
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ure 4C). We found that the DN RBFOX2 isoform lacking exon 6
was increased in both T1D mouse models (non-obese diabetic
[NOD] and streptozotocin [STZ] induced) as well as in T2D hu-
man patients’ hearts (Figures 4D–4F). To determine whether
expression of DN Rbfox2 is an early event in diabetic cardiomy-
opathy, we examined cardiac function before and after induction
of diabetes by STZ using echocardiography. Left ventricle (LV)
function, stroke volume, and ventricular internal diameter end
at diastole (LVIDd) were unaffected after 3 weeks of hyperglyce-
mia (Figures 4G–4I). These results show that DN Rbfox2 upregu-
lation and changes in AS of RBFOX2 targets occurred before
cardiac complications were detectable in diabetic mice, indi-
cating that DN Rbfox2 expression is an early response to high
glucose levels. We also examined DNRbfox2 expression in other
mouse models. DN Rbfox2 mRNA levels were not increased in
hypertensive, obese, obese-hypertensive, or mice with cardio-
myopathy when compared to controls (Figures 4J and 4K).
Consistent with these mouse models’ lack of increase in DN
Rbfox2 expression, AS patterns of RBFOX2 targets were also
unaffected (Figures 4J and 4K versus Figures 2B, 2E, and S2).
These results show that the DN version of RBFOX2 is generated
in both T1D mouse and T2D patients’ hearts as an early event,
and the expression of DN RBFOX2 is consistent with aberrant
AS of RBFOX2 targets in diabetic hearts.
Increased RBFOX2 Protein Levels with RNA-binding
Capability Induce DN Rbfox2 Expression
We investigated how DN RBFOX2 is generated in diabetic
hearts. RBFOX2 AS activity is controlled such that an increase
in RBFOX2 protein levels leads to expression of the DN version
via autoregulation of exon 6 exclusion (Damianov and Black,
2010). We tested whether DN Rbfox2 is generated due to high
levels of RBFOX2 and whether RNA-binding activity of RBFOX2
is required. We expressed RBFOX2 in H9c2 cells and examined
endogenous DN Rbfox2 expression by qRT-PCR. As a control,
an RNA-binding-deficient mutant of RBFOX2 (RBFOX2RRM)
was expressed. RBFOX2RRM mutant lacks RNA-binding activity
due to mutagenesis of two critical phenylalanine residues in the
RRM necessary for RNA-binding (Auweter et al., 2006; Mayeda
et al., 1994; Sun et al., 2012). We found that overexpression of
RBFOX2WT (Figure 5A) capable of binding to RNA increased
the expression of the DN Rbfox2 isoform (Figure 5B). However,
RBFOX2RRM mutant (Figure 5A) did not affect DN expression
as robustly as the WT (Figure 5B), demonstrating that the RNA-
binding function of RBFOX2 is critical for autoregulation and
DN Rbfox2 generation.using qRT-PCR from left ventricles of T2D human patients or non-diabetic
diabetic (NOD:T1D) mice (nR 4).
-induced T1D (STZ:T1D3wks) mice hyperglycemic for 3 weeks (nR 3).
(STZ:T1D3wks) was assessed by M-mode echocardiography measuring (G)
eter end at diastole (LVIDd) (mm; nR 3).
myopathy or mock-infected controls (nR 3).
bese-hypertensive mouse left ventricles (n = 3).
calculated using the unpaired t test and between four groups using one-way
Figure 5. Increased RBFOX2 Protein with RNA-binding Capability Is Important for Generation of DN Rbfox2
(A) WB analysis of RBFOX2 in H9c2 cells expressing empty vector (control), RBFOX2WT, or RBFOX2RRM (RNA-binding-deficient mutant).
(B) Endogenous DN Rbfox2 expression by exclusion of exon 6 in H9c2 cells expressing control, RBFOX2WT, or RBFOX2RRM determined by qRT-PCR (n = 4 from
three independent experiments). Data represent the means ± SD.
(C) RBFOX2 WB in H9c2 cells expressing GFP or increasing levels of GFP-tagged RBFOX2 using anti-GFP or anti-RBFOX2 Ab. Ponceau S staining was used to
assess even protein loading.
(legend continued on next page)
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Next, we examined whether there is a threshold for RBFOX2
protein levels to have an inhibitory splicing effect by generating
DN RBFOX2. To test this, we performed a dose response exper-
iment by expressing increasing concentrations of GFP-RBFOX2
but keeping total transfected DNA concentration the same and
tested AS of RBFOX2 targets. Expression levels of endogenous
DN Rbfox2 were also monitored. As a negative control, we used
GFP. Figure 5C shows an exponential increase in GFP-RBFOX2
protein levels determined by western blot (WB) using both GFP
and RBFOX2 antibodies. At the lowest dose of WT RBFOX2,
all four exons targeted by RBFOX2 were affected such that
Mef2a, Mtmr3, and Fxr1 alternative exons were more included
(Figures 5D and S3). However, as the RBFOX2 dose increased,
Mef2a exon 6 inclusion was inhibited (Figure 5D) and exon inclu-
sions of Mtmr3 and Fxr1 were not further increased, coinci-
dent with upregulation of endogenous DN Rbfox2 (Figure 5E).
Because the endogenous Rbfox2 pre-mRNA level is the limiting
factor in generation of DN RBFOX2 in response to high levels of
WT RBFOX2, it is possible that only exons very sensitive to
changes in RBFOX2 were inhibited and others were prevented
at high WT RBFOX2 doses. On the contrary, exon 6 exclusion
of Rbfox2 was not inhibited at any concentration of WT RBFOX2
(Figure 5E) that adversely affected exon inclusions (Figures 5D
and S3). Indeed, Rbfox2 exon 6 was excluded continuously
from 92% to 36% as the WT RBFOX2 concentrations increased,
suggesting that WT RBFOX2 was not effective in inhibiting exon
6 exclusion; thus, DN Rbfox2 generation (Figure 5E). To test
whether WT RBFOX2 overexpression has any effect on other
exon exclusion events, we analyzed Mbnl2 exon 8. At low WT
RBFOX2 dose, Mbnl2 exon 8 inclusion decreased from 67% to
42% (Figure 5E). At higher doses of WT RBFOX2, Mbnl2 exon
8 was 10% further excluded down to 32% (Figure 5E). Whereas
Mbnl2 and Rbfox2 exons continued to be excluded as WT
RBFOX2 concentration increased, exon inclusion events were
either inhibited or prevented. These results suggest that overex-
pression of WT RBFOX2 may be ineffective in inhibiting exon
exclusion. Overall, aberrant upregulation of RBFOX2 above a
threshold becomes ineffective or even inhibitory in regulating
RBFOX2-dependent exon inclusion.
Increased RBFOX2 Protein Levels during Myocardial
Differentiation Correlates with Upregulation of DN
Rbfox2
RBFOX2 protein levels are dynamically regulated during cardio-
myocyte differentiation (Verma et al., 2013). To further test
whether high RBFOX2 protein levels are responsible for DN
Rbfox2 induction, we examined DN Rbfox2 expression during
cardiomyocyte differentiation. Successful differentiation was
confirmed by upregulation of cardiac troponin T (cTNT) using
WB (Figure S4A). In differentiated cells, RBFOX2 protein levels
were elevated by 3.6-fold, corresponding to a 40% increase in(D and E) AS of (D) Mef2a and Mtmr3 and (E) Mbnl2 and expression levels of DN
Figure S3). To equalize the amount of DNA per plate to 2 mg, different concentra
cations were performed using samples from at least four independent experimen
Data represent the means ± SE. Statistical significance was calculated using one-
as **** < 0.0001, *** < 0.001, and ** < 0.01 compared to the GFP control (0 mg RBF
lowest RBFOX2WT-GFP level (0.2 mg RBFOX2 DNA).
2208 Cell Reports 15, 2200–2213, June 7, 2016DN Rbfox2 expression when compared to undifferentiated cells
(Figures S4A and S4B). These results support our findings that,
when RBFOX2 levels increase over a threshold, it induces DN
expression (Figures 4, 5, and S4).
DN RBFOX2 Interacts with WT RBFOX2 and Inhibits AS
of RBFOX2 Targets
The next important question was to determine whether ectopic
expression of DN RBFOX2 inhibits AS similar to that observed
in diabetic hearts. For that reason, we expressed FLAG-DN
RBFOX2 in H9c2 cells (Figure 6A) and tested AS of RBFOX2-
responsive targets. FLAG-DN RBFOX2 expression induced
exon exclusion of targets (Figure 6B) resembling AS patterns in
diabetic hearts (Figure 6B versus Figure 2A). This result indicates
that the DN RBFOX2 upregulation in diabetic hearts impairs
RBFOX2-dependent splicing.
To investigate whether DN RBFOX2 inhibits splicing via
sequestering spliceosome components known to interact with
RBFOX2, we overexpressed either FLAG-tagged WT or DN
RBFOX2 in COS M6 cells and performed FLAG immunoprecipi-
tation (IP) to assess the binding of RBFOX2 to U1 snRNP. It was
previously shown that RBFOX2 binds to U1C to assemble the U1
small nuclear ribonucleoprotein particle (snRNP) complex and
promote splicing (Huang et al., 2012). We also tested whether
the RNA-binding-deficient mutant of RBFOX2 (RBFOX2RRM)
can interact with U1C. To determine whether there is non-spe-
cific protein binding to the FLAG-antibody-coated beads, we
used protein lysates from cells expressing empty vector (con-
trol). Loading control shows equal amounts of lysates (input)
loaded onto beads coated with similar amounts of FLAG-anti-
body (immunoglobulin G [IgG]; Figures 6C and 6D). As expected,
WT RBFOX2 pulled down endogenous U1C protein (Figure 6C).
However, neither RBFOX2RRM nor DN RBFOX2 was able to pull
down U1C (Figure 6C), indicating that RBFOX2 mutants lacking
RNA-binding activity do not interact with U1C. DN proteins are
known to bind to the WT protein counterpart to inhibit activity.
To test whether DNRBFOX2 interacts withWTRBFOX2 to inhibit
its splicing activity, we co-expressed GFP-WT RBFOX2 with
FLAG-DN RBFOX2 and performed FLAG-IP. GFP-WT RBFOX2
was pulled down together with FLAG-DN RBFOX2, indicating
that DN andWT RBFOX2 proteins interact (Figure 6D). These re-
sults suggest that DNRBFOX2 inhibits AS via interactingwithWT
RBFOX2 not by sequestering U1C.
Dysregulation of RBFOX2 Adversely Affects
Cytoskeleton-Associated Gene Function and
Intracellular Calcium Handling
To determine the consequences of RBFOX2-induced AS de-
fects, we focused on the downstream targets of RBFOX2. Abla-
tion of the RBFOX2 target gene Fxr1 in animal models causes
cardiomyopathy, partly by upregulation of the TALIN2 protein,Rbfox2 in H9c2 cells expressing increasing levels of RBFOX2WT-GFP (see also
tions of vector DNA were transfected together with RBFOX2WT-GFP. Quantifi-
ts (nR 4).
way ANOVA to compare three or more different groups. p values are indicated
OX2 DNA). p values indicated as #### < 0.0001 represent comparisons to the
Figure 6. DN RBFOX2 Interacts with WT RBFOX2 and Inhibits AS of RBFOX2-Regulated Splicing
(A) WB analysis of DN RBFOX2 protein in H9c2 cells expressing empty vector (control) or FLAG-RBFOX2DN.
(B) AS analysis of Mtmr3, Fxr1, and Mef2a in H9c2 cells transfected with empty vector (control) or FLAG-RBFOX2DN (nR 4).
(C) Interactions of FLAG-taggedRBFOX2WT, RBFOX2DN, and RBFOX2RRM (RNA-binding-deficientmutant) with U1C protein in COSM6 cells determined by FLAG
IP followed by WB using FLAG and U1C-specific Abs.
(D) Interactions of FLAG-RBFOX2DN with GFP-RBFOX2WT in H9c2 cells. Pulled-down proteins were analyzed byWB using HRP-conjugated anti-FLAG and anti-
GFPAbs. Control lysates expressing empty vector were used as a negative control for non-specific protein binding to the FLAG-antibody-coated beads (FLAG-IP
control). Input lysates represent 1/20 of total protein loaded onto the FLAG beads. Results are representative of three independent experiments.which functions in the assembly of the actin cytoskeleton (Whit-
man et al., 2011). FXR1 exons 15 and 16, necessary for striated
muscle-specific translational regulation (Kirkpatrick et al., 1999),
are almost completely excluded in diabetic human hearts (Fig-
ure 2A) and in RBFOX2-depleted cells (Figures 3D and 3E).
When we checked TALIN2 protein levels in RBFOX2-depleted
cells, TALIN2 protein levels were significantly elevated (Fig-
ure 7A). TALIN2 protein levels were also upregulated in T1D
mouse hearts (Figure 7B). This result shows that low RBFOX2
levels/activity correlates with increased TALIN2 protein levels
in diabetic mouse hearts.
Next, we tested whether DN RBFOX2 expression affects car-
diomyocyte function. It has been previously shown that ablation
of Rbfox2 in adult mouse hearts impairs excitation:coupling (Wei
et al., 2015), and our results show that RBFOX2 targets affectedin diabetic hearts have functions in calcium homeostasis (Fig-
ure 1C). Thus, we examined intracellular calcium handling in hu-
man cardiomyocytes expressing DN RBFOX2. DN RBFOX2
expression induced a delayed upstroke of the calcium transients
in cardiomyocytes (Figures 7C and 7D) without a change in cal-
cium transient amplitudes (Figure 7E), indicating a defect in intra-
cellular calcium handling, which is necessary for cardiomyocyte
contraction. In sum, our results show that DN RBFOX2 may
contribute to diabetes pathogenesis by altering intracellular cal-
cium signaling.
DISCUSSION
We have previously shown that AS is dysregulated in diabetic
hearts. Our goal in this study was to determine the responsibleCell Reports 15, 2200–2213, June 7, 2016 2209
Figure 7. Consequences of Aberrant AS of
RBFOX2 Targets
(A) WB analysis of TALIN2 (TLN2), RBFOX2, and
GAPDH in H9c2 cells treated with scrambled
siRNA (control) or Rbfox2-specific siRNA. Fold
changes in TLN2 protein levels were determined
after normalizing to GAPDH protein levels (n R 9
from three independent experiments).
(B) Representative WB analysis of TLN2 protein
levels in STZ:T1D mice. a-TUBULINWB was used
as a loading control. Fold changes in TLN2 levels
were determined after quantifying protein levels
and normalizing to a-TUBULIN levels. TLN2
levels in control mice were set as 1. Average
values were represented as means ± SD (n = 4).
(C) Representative tracing of calcium transients
from human primary cardiomyocytes infected with
AAV9-CMV-null (control) and AAV9-CMV-DN
RBFOX2 (DN RBFOX2).
(D and E) Quantification of (D) time to peak and (E)
amplitude of calcium transients. The numbers in
the bar graphs represent the number of car-
diomyocytes used for quantification from three
independent experiments.
Statistical significance was calculated using the
unpaired t test to compare twogroups. p valuesare
indicated as **** < 0.0001, ** < 0.01, and * < 0.05.AS regulators. We found that the RNA-binding protein RBFOX2
contributes to AS defects in the heart under diabetic conditions.
Comparing our RNA sequencing data from diabetic mouse
hearts to the RBFOX2 CLIP-seq data (NCBI: SRP030031 and
SRP029987), we found that RBFOX2 binds to 73% of transcripts
that are differentially spliced. In diabetic hearts, RBFOX2-bind-
ing clusters were significantly enriched in mis-spliced transcripts
in comparison to control transcripts that were not mis-spliced
but displayed similar expression levels. Importantly, we found
that RBFOX2 controls AS of target genes with RBFOX2-binding
sites and that AS changes impair normal gene expression pat-
terns in the heart, especially genes important for macromolec-
ular metabolism, apoptosis, calcium homeostasis, and protein
trafficking. Supporting these findings, expression of DNRBFOX2
in cardiomyocytes impaired intracellular calcium handling.
We found that RBFOX2 autoregulation is disrupted in diabetic
hearts at early stages before cardiac complications are evident.
RBFOX2-mediated splicing function was low in diabetic hearts
due to the expression of the DN RBFOX2. A recent study has
shown that heart-specific deletion of Rbfox2 in mice induces2210 Cell Reports 15, 2200–2213, June 7, 2016dilated cardiomyopathy (Wei et al.,
2015). Our results demonstrate that
expression of DN RBFOX2, which inhibits
RBFOX2-dependent splicing, adversely
affects calcium handling in human cardi-
omyocytes. These results support the
conclusion that increased DN RBFOX2
expression in diabetic hearts contributes
to cardiac complications.
In this study, we discovered that a DN
isoform of RBFOX2 is upregulated inhearts of both human diabetic patients and mouse models via
skipping of exon 6 induced by an increase in RBFOX2
protein levels. This isoform was identified as an inhibitor of
RBFOX AS activity in cultured cells (Damianov and Black,
2010; Nakahata and Kawamoto, 2005). RBFOX2 has consensus
binding sites in the flanking introns of exon 6, which is skipped
in the DN isoform (Damianov and Black, 2010). Here, we
showed that increased RBFOX2 protein in diabetes is important
for DN RBFOX2 production in diabetic hearts and found
that RBFOX2 RNA-binding capability is critical for generation
of DN RBFOX2 via AS. Therefore, it is likely that RBFOX2 binds
to its own pre-mRNA to promote exon 6 exclusion and DN
expression.
An important part of our finding is that the dysregulation of
AS in diabetic hearts is in agreement with the upregulation of
DN RBFOX2. Notably, RBFOX2 target AS events were unaf-
fected in obese and hypertensive mice that do not upregu-
late DN Rbfox2. We also found that RBFOX2-regulated AS
events remained unchanged in mouse hearts with chagasic car-
diomyopathy in which DN Rbfox2 expression is not induced.
These results indicate that the expression of DN RBFOX2 is
stimulated under diabetic conditions independent of hyperten-
sion and obesity. In addition, DN RBFOX2 overexpression
impaired AS of RBFOX2 targets. Here, we provide strong evi-
dence for mode of inhibitory function of DN RBFOX2 on
RBFOX2-dependent splicing by finding that DN RBFOX2 inter-
acts with WT RBFOX2 but does not interact with the
U1snRNP-associated U1C.
In our study, FXR1 exons 15 and 16 were almost completely
skipped in diabetic human hearts. FXR1 regulates mRNA trans-
lation of TALIN2, an important regulator of actin assembly
(Whitman et al., 2011). FXR1 knockout mice develop cardiomy-
opathy in part due to increased translation and accumulation
of TALIN2 (Whitman et al., 2011). Our data indicate that RBFOX2
knockdown results in exclusion of Fxr1 exon 15 and 16 and,
in turn, high TALIN2 levels similar to the levels observed in dia-
betic hearts. These results suggest a role for RBFOX2 in regu-
lating cytoskeleton-interacting protein contributing to diabetic
cardiomyopathy.
In summary, we find that 704 alternative exons mis-spliced in
diabetic hearts are RBFOX2 targets. RBFOX2 protein levels go
up in diabetic hearts, inducing an AS change in RBFOX2 pre-
mRNA that generates a DN isoform with inhibitory AS function,
contributing to AS changes with adverse effects on gene expres-
sion and function. Importantly, DN RBFOX2 is generated specif-
ically in diabetic hearts at early stages, making it a potential
diagnostic marker for diabetic cardiomyopathy. Identifying
RBFOX2 as an important contributor to AS changes and diabetic
complications and determining how it is dysregulated may allow
us to develop novel tools to diagnose, prevent, or treat diabetic
cardiomyopathy in the future.
EXPERIMENTAL PROCEDURES
Animal Experiments
Animal models used for this study are as follows: STZ-induced T1D and NOD,
obese, hypertensive, obese-hypertensive, and chagasic mice. Details about
these mouse models are found in the 16-00055 Supplemental Experimental
Procedures.
All animal experiments were conducted in accordance with the NIH guide-
lines and approved by the University of Texas Medical Branch Institutional
Animal Care and Use Committee (protocol no. 1101001).
Echocardiography
Cardiac function was assessed using M-mode echocardiography with a
Visual Sonics VeVo 2100 ultrasound and a 30 MHz probe at the UTMB
Biomedical Imaging Network. Mice were anesthetized (1.5% isoflurane mixed
with 95% oxygen) and maintained on a heated platform with echocardiogram
(ECG) electrodes to measure body heat and heart rate before and during
the imaging. Mice with a heart rate of 450 ± 50 and body temperature of at
least 37C were used for all analyses. Fractional shortening, stroke volume,
and LVIDd were calculated as described previously (Liu et al., 2012) using
Visual Sonics software at the Baylor College of Medicine Mouse Phenotyping
Core.
Human Tissue
Human heart tissues (diabetic and non-diabetic) were obtained from the
National Disease Research Interchange. Two additional non-diabetic human
heart tissues were obtained from Dr. Nisha Garg at the University of Texas
Medical Branch. All human heart tissues used in this study were pre-existing
and deidentified. Thus, human tissue use was exempt from Institute Review
Board regulations (protocol no. 11-087).Cell Culture, Differentiation, and Transfections
Cells were cultured and transfected using standard procedures as previously
described (Verma et al., 2013). H9c2 cells were differentiated into cardiomyo-
cyte-like cells as described previously (Verma et al., 2013). Human Prenatal
Primary Cardiomyocytes (DV Biologics) were cultured according to the manu-
facturer’s protocols and infected with AAV9 virus (Vector Biolabs) to express
either empty vector or DN RBFOX2. Details are found in the Supplemental
Experimental Procedures.
Calcium Imaging
For calcium imaging, human primary cardiomyocytes (DV Biologics) were
incubated at 20C with 8 mM calcium indicator Fluo-4-AM (Life Technologies;
F14201) for 10 min and imaged in Hank’s balanced salt solution (pH 7.4) using
an Olympus IX51 microscope (203) and CelSens Standard version 1.4.1
software.
RNA Sequencing, RBFOX2-binding Site Overlay, and Statistical
Analysis
An Illumina HiSeq 1000 system was used for paired end (2 3 15 cycles) RNA
sequencing at the UTMB Next-Generation Sequencing Core facility (Verma
et al., 2013). Approximately 200 million reads per sample were generated.
Changes in AS were determined using the mixture-of-isoforms (MISO) model
(Katz et al., 2010). To determine RBFOX2-binding sites on transcripts mis-
spliced in diabetic mouse hearts, human hg19 RBFOX2 CLIP data (Yeo
et al., 2009) were converted to the mm9 mouse genome coordinates using
liftOver (Hinrichs et al., 2006). AS events, which displayed an absolute delta
Psi > = 0.1 were used for this analysis. The number of events with at least
one CLIP peak at a Bayes factor (BF) cutoff of 1 was set as ‘‘significant’’
and BF < 1 was set as ‘‘not significant.’’ For RBFOX2-binding cluster anal-
ysis, AS events that did not change significantly between all individual
comparisons among six samples but exhibited similar expression levels in
diabetic hearts were used as controls. Statistical analysis of AS events
that were differentially included or excluded in diabetes was determined by
calculating a hypergeometric p value of the enrichment of significant AS
events, which contained an RBFOX2 CLIP peak in the region of interest,
versus the control AS events with RBFOX2 CLIP peaks (Dale et al., 2011;
Perez and Granger, 2007; Quinlan and Hall, 2010). Genes with RBFOX2-
binding sites were categorized based on their biological or molecular
function using the DAVID server (version 6.7) with the whole genome as a
background control.
qRT-PCR and Statistical Analysis
qRT-PCR was performed to detect inclusion/exclusion of gene-specific alter-
native exons and relative mRNA levels. Details are included in the Supple-
mental Experimental Procedures. Student’s t test was used to determine
statistical significance between two groups and one-way ANOVA for compar-
isons of more than two groups with Bonferroni correction using Prism
software.
FLAG Immunoprecipitation/Western Blot Analysis
For IP assays, a FLAG IP kit (Sigma FLAGIPT1-1KT) was used to pull
down FLAG-tagged WT, DN, or RNA-binding-deficient mutant RBFOX2
expressed in COS M6 or H9c2 cells per the manufacturer’s protocol.
Precipitated proteins were analyzed on 4%–15%gradient SDS-PAGE gels fol-
lowed by WB analysis using an anti-FLAG antibody (Ab) conjugated to horse-
radish peroxidase (HRP) (Sigma A8595), anti-GFP Ab conjugated to HRP
(Santa Cruz Biotechnology sc9996), or anti-U1C Ab (Bethyl Laboratories
A303-947A).
WB analyses were performed as previously described (Verma et al., 2013).
Details are included in the Supplemental Experimental Procedures.
Plasmid Generation
A human RBFOX2 mutant deficient in RNA-binding (RBFOX2RRM) was gener-
ated by mutating two phenylalanine (F153 and F155) residues necessary for
RNA-binding in the RRM into aspartate residues (Auweter et al., 2006; Mayeda
et al., 1994; Sun et al., 2012).Cell Reports 15, 2200–2213, June 7, 2016 2211
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